The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

Nature Reviews Drug Discovery

Volumn 11, Issue 2, 2012, Pages 168-

  Spellberg, Brad ^a   Sharma, Priya ^b   Rex, John H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG POTENCY; DRUG RESEARCH; ECONOMIC ASPECT; ECONOMIC INCENTIVE; LETTER; PATENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SENSITIVITY ANALYSIS; VALIDITY;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 84856461571     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3560-c1     Document Type: Letter

References (14)

1. Powers, J. H. & Laxminarayan, R. Antibacterial R&D incentives. Nature Rev. Drug Discov. 10, 727-728 (2011).
2. European Medicines Agency. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. EMA website [online], www.ema.europa.eu/pdfs/human/antimicrobial-resistance/53394009en.pdf (2009).
3. Spellberg, B. et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52, S397-S428 (2011).
4. Mossialos, E. et al. Policies and incentives for promoting innovation in antibiotic research. LSE website [online], http://www2.lse.ac.uk/ LSEHealthAndSocialCare/LSEHealth/News/Antibiotics%20Report.aspx (2009).
5. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. IDSA website [online], http://www.idsociety.org/uploadedFiles/IDSA/Policy-and-Advocacy/ Current-Topics-and-Issues/Antimicrobial-Resistance/10x20/Images/ Bad%20Bugs%20no%20 Drugs.pdf (2004).
6. Sharma, P. & Towse, A. New drugs to tackle antimicrobial resistance: analysis of EU policy options. http://www.ohe.org/publications/article/new- drugs-to-tackle-antimicrobial-resistance-5.cfm OHE website [online], (2011).
7. Claxton, K., Paulden, M., Gravelle, H., Brouwer, W. & Culyer, A. J. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 20, 2-15 (2011).
8. Bos, J. M., Postma, M. J. & Annemans, L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 23, 639-649 (2005). (Pubitemid 41003073)
9. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010).
10. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003). (Pubitemid 36279392)
11. DiMasi, J. A. & Grabowski, H. G. The cost of biopharmaceutical R&D: is biotech different? Manag. Decision Econ. 28, 469-479 (2007).
12. Stewart, J. J., Allison, P. N. & Johnson, R. S. Putting a price on biotechnology. Nature Biotech. 19, 813-817 (2001). (Pubitemid 32816750)
13. Papadopoulos, S. Quantifying the dream: valuation approaches in biotechnology. Nature Biotech.16, S55-S56 (1998).
14. Avance. Discount rates for biotech companies. News in Avance: Valuations in Life Sciences. Avance website [online], http://www.avance.ch/newsletter/docs/ Discount-1.pdf (2008).